New concepts on the role of human papillomavirus in cell cycle regulation

Annals of Medicine

Volumn 31, Issue 3, 1999, Pages 175-187

  Syrjänen, Stina M ^a,b   Syrjänen, Kari J ^b,c  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Cell cycle; Cyclin dependent kinases; Cyclins; E proteins E2, E5, E6, E7; Keratinocyte; Malignant transformation; Papillomavirus

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53;

CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL ONCOGENE; CELL PROLIFERATION; ENZYME ACTIVE SITE; GENE EXPRESSION; GENOME; HUMAN; KERATINOCYTE; MALIGNANT TRANSFORMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SQUAMOUS EPITHELIUM; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

EID: 0033018458     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899909115976     Document Type: Review

References (128)

1. International Agency for Research on Cancer (IARC) Papillomaviruses. Monographs on the evaluation of carcinogenic risks to humans. Vol 64. Lyon: IARC; 1995.
2. zur Hausen H. Viruses in human tumors - reminiscences and perspectives. Adv Cancer Res 1996; 68: 1-22.
3. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996; 1288: F55-78.
4. zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 1996; 122: 3-13.
5. Syrjänen K, Syrjänen S. Papillomavirus Infections in Human Pathology. New York: Wiley (in press).
6. Stern PL, Stanley MA, eds. Human Papillomaviruses and Cervical Cancer. Biology and Immunology. Oxford: Oxford University Press; 1994.
7. zur Hausen H, ed. Human pathogenic papillomaviruses. Curr Top Microbiol Immunol 1994; 186: 1-266.
8. zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994; 48: 427-47.
9. Myers G, Lu H, Calef C, Leitner T. Heterogeneity of papillomaviruses. Semin Cancer Biol 1996; 7: 349-58.
10. Arndt O, Johannes A, Zeise K, Brock J. "High risk" HPV types in oral and laryngeal papillomas and in laryngeal leukoplakia. Laryngol Rhinol Otol 1997; 76: 142-9.
11. deVilliers EM. Papillomavirus and HPV typing. Clin Dermatol 1997; 15: 199-206.
12. Favre M, Ramoz N, Orth G. Human papillomaviruses: general features. Clin Dermatol 1997; 15: 181-98.
13. Jablonska S, Majewski S, Obalek S, Orth G. Cutaneous warts. Clin Dermatol 1997; 15: 309-19.
14. Orth G, Jablonska S. Papillomavirus: part one. Clin Dermatol 1997; 15: 179-80.
15. Wright TC, Sun XW. Anogenital papillomavirus infection and neoplasia in immunodeficient women. Obstet Gynecol Clin North Am 1996; 23: 861-93.
16. Pfister H, Fuchs PG. Anatomy, taxonomy and evolution of papillomaviruses. Intervirology 1994; 37: 143-9.
17. Fuchs PG, Pfister H. Transcription of papillomavirus genomes. Intervirology 1994; 37: 159-67.
18. Turek LP. The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. Adv Virus Res 1994; 44: 305-56.
19. Hoppe-Seyler F, Butz K. Cellular control of human papillomavirus oncogene transcription. Mol Carcinog 1994; 10: 134-41.
20. Auborn KJ, Wang H, Vaccariello MA, Taichman LB. Kinetics of HPV11 DNA replication after infection of keratinocytes with virions. Virus Res 1996; 43: 85-90.
21. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73: 1059-65.
22. O'Connor PM. Mammalian G1 and G2 phase checkpoints. Cancer Surv 1997; 29: 151-82.
23. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995; 11: 211-9.
24. Arellano M, Moreno S. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 1997; 29: 559-73.
25. Desdouets C, Sobczak-Thepot J, Murphy M, Brechot C. Cyclin A: function and expression during cell proliferation. Prog Cell Cycle Res 1995; 1: 115-23.
26. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays 1997; 19: 307-15.
27. Pines J. The cell cycle kinases. Semin Cancer Biol 1994; 5: 305-13.
28. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998; 12: 845-59.
29. Livneh E, Fishman DD. Linking protein kinase C to cell-cycle control. Eur J Biochem 1997; 248: 1-9.
30. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5: 127-56.
31. Lawrence DA. Transforming growth factor-beta: a general review. Eur Cytokine Netw 1996; 7: 363-74.
32. Mayol X, Grana X. pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. Prog Cell Cycle Res 1997; 3: 157-69.
33. Phelps WC, Bagchi S, Barnes JA. Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J Virol 1991; 65: 6922-30.
34. Morris JD, Crook T, Bandara LR, Davies R, Lathangue NB, Vousden KH. Human papillomavirus type 16 E7 regulates E2F and contributes to mitogenic signalling. Oncogene 1993; 8: 893-8.
35. Kubbutat MHG, Vousden KH. Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Semin Virol 1996; 7: 295-304.
36. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358: 259-61.
37. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 1993; 7: 1850-61.
38. Hickman ES, Bates S, Vousden KH. Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol 1997; 71: 3710-8.
39. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-21.
40. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
41. Kastan MB, Zhan Q, El Deiry WS, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-97.
42. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
43. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-8.
44. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 1994; 13: 4816-22.
45. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646-9.
46. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
47. Galloway DA, Demers GW, Foster SA, Halbert CL, Russell K. Cell cycle checkpoint control is bypassed by human papillomavirus oncogenes. Cold Spring Harb Symp Quant Biol 1994; 59: 297-306.
48. Jones DL, Munger K. Analysis of the p53-mediated G(1) growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997; 71: 2905-12.
49. Bernard HU. Controls in the papillomavirus life cycle. FEMS Microbiol Immunol 1990; 64: 201-6.
50. Ham J, Dostatni N, Gauthier JM, Yaniv M. The papillomavirus E2 protein: a factor with many talents. Trends Biochem Sci 1991; 16: 440-4.
51. McBride AA, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. J Biol Chem 1991; 266: 18411-4.
52. Giri I, Yaniv M. Study of the E2 gene product of the cottontail rabbit papillomavirus reveals a common mechanism of transactivation among papillomaviruses. J Virol 1988; 62: 1573-81.
53. Barsoum J, Prakash SS, Han P, Androphy EJ. Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding. J Virol 1992; 66: 3941-5.
54. Desaintes C, Hallez S, Detremmerie O, Burny A. Wild-type p53 down-regulates transcription from oncogenic human papillomavirus promoters through the epithelial specific enhancer. Oncogene 1995; 10: 2155-61.
55. Drummond-Barbosa DA, Vaillancourt RR, Kazlauskas A, DiMaio D. Ligand-independent activation of the plateletderived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol Cell Biol 1995; 15: 2570-81.
56. Drummond-Barbosa D, DiMaio D. Virocrine transformation. Biochim Biophys Acta 1997; 1332: M1-17.
57. Flores ER, Lambert PF. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol 1997; 71: 7167-79.
58. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997; 16: 504-14.
59. Bubb V, McCance DJ, Schlegel R. DNA sequence of the HPV-16 E5 ORF and the structural conservation of its encoded protein. Virology 1988; 163: 243-6.
60. Halbert CL, Galloway DA. Identification of the E5 open reading frame of human papillomavirus type 16. J Virol 1988; 62: 1071-5.
61. Leptak C, Ramon Y, Kulke R, Horwitz BH, Riese DJ, Dotto GP, et al. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virol 1991; 65: 7078-83.
62. Leechanachai P, Banks L, Moreau F, Matlashewski G. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 1992; 7: 19-25.
63. Pim D, Collins M, Banks L. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 1992; 7: 27-32.
64. Straight SW, Hinkle PM, Jewers RJ, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J Virol 1993; 67: 4521-32.
65. Bouvard V, Matlashewski G, Gu ZM, Storey A, Banks L. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology 1994; 203: 73-80.
66. Hwang JY, Lin BY, Tang FM, Yu WCY. Tamoxifen stimulates human papillomavirus type-16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res 1992; 52: 6848-52.
67. Straight SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol 1995; 69: 3185-92.
68. Crusius K, Auvinen E, Steuer B, Gaissert H, Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 1998; 241: 76-83.
69. Conrad M, Goldstein D, Andresson T, Schlegel R. The e5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors. Virology 1994; 200: 796-800.
70. Kulke R, DiMaio D. Biological properties of the deer papillomavirus E5 gene in mouse C127 cells: growth transformation, induction of transformation. J Virol 1991; 4943-9.
71. Petti L, DiMaio D. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proc Natl Acad Sci U S A 1992; 89: 6736-40.
72. Meyer AN, Xu YF, Webster MK, Smith AE, Donoghue DJ. Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus e5 oncoprotein. Proc Natl Acad Sci U S A 1994; 91: 4634-8.
73. Nilson LA, Gottlieb RL, Polack GW, DiMaio D. Mutational analysis of the interaction between the bovine papillomavirus e5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse c127 cells. J Virol 1995; 69: 5869-74.
74. Sparkowski J, Anders J, Schlegel R. E5 oncoprotein retained in the endoplasmic reticulum/cis golgi still induces PDGF receptor autophosphorylation but does not transform cells. EMBO J 1995; 14: 3055-63.
75. Petti L, DiMaio D. Specific interaction between the bovine papillomavirus e5 transforming protein and the beta receptor for platelet-derived growth factor in stably transformed and acutely transfected cells. J Virol 1994; 68: 3582-92.
76. Petti LM, Reddy V, Smith SO, DiMaio D. Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein. J Virol 1997; 71: 7318-27.
77. Goldstein DJ, Andresson T, Sparkowski JJ, Schlegel R. The BPV-1 e5-protein, the 16-kda membrane pore-forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. EMBO J 1992; 11: 4851-9.
78. Maher DW, Strawn LM, Donoghue DJ. Alanine mutagenesis of conserved residues in the platelet-derived growth factor family - identification of residues necessary for dimerization and transformation. Oncogene 1993; 8: 533-41.
79. Cohen BD, Goldstein DJ, Rutledge L, Vass WC, Lowy DR, Schlegel R, et al. Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain. J Virol 1993; 67: 5303-11.
80. Gu Z, Matlashewski G. Effect of human papillomavirus type 16 oncogenes on MAP kinase activity. J Virol 1995; 69: 8051-6.
81. Crusius K, Auvinen E, Alonso A. Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 1997; 15: 1437-44.
82. Tsao YP, Li LY, Tsai TC, Chen SL. Human papillomavirus type 11 and 16 E5 represses p(21WafI/SdiI/CipI) gene expression in fibroblasts and keratinocytes. J Virol 1996; 70: 7535-9.
83. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus e6 oncoproteins with a putative calcium-binding protein. Science 1995; 269: 529-31.
84. Chen SL, Tsai TC, Han CP, Tsao YP. Mutational analysis of human papillomavirus type 11 E5a oncoprotein. J Virol 1996; 70: 3502-8.
85. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991; 65: 473-8.
86. Sedman SA, Barbosa MS, Vass WC, Hubbert NL, Haas JA, Lowy DR, et al. The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 1991; 65: 4860-6.
87. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990; 87: 463-7.
88. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
89. Keen N, Elston R, Crawford L. Interaction of the e6 protein of human papillomavirus with cellular proteins. Oncogene 1994; 9: 1493-9.
90. Weis K, Griffiths G, Lamond AI. The endoplasmic reticulum calcium-binding protein of 55 kDa is a novel EF-hand protein retained in the endoplasmic reticulum by a carboxylterminal His-Asp-Glu-Leu motif. J Biol Chem 1994; 269: 19142-50.
91. Kim KH, Yoon DJ, Moon YA, Kim YS. Expression and localization of human papillomavirus type 16 E6 and E7 open reading frame proteins in human epidermal keratino-cyte. Yonsei Med J 1994; 35: 1-9.
92. Etscheid BG, Foster SA, Galloway DA. The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. Virology 1994; 205: 583-5.
93. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, Ishibashi M. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997; 94: 11612-6.
94. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
95. Marston NJ, Crook T, Vousden KH. Interaction of p53 with MDM2 is independent of e6 and does not mediate wild type transformation suppressor function. Oncogene 1994; 9: 2707-16.
96. Mansur CP, Marcus B, Dalal S, Androphy EJ. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain. Oncogene 1995; 10: 457-65.
97. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10: 4129-35.
98. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 1992; 66: 5100-5.
99. Ciechanover A. The ubiquitin-mediated proteolytic pathway: mechanisms of action and cellular physiology. Biol Chem Hoppe Seyler 1994; 375: 565-81.
100. Hochstrasser M, Papa FR, Chen P, Swaminathan S, Johnson P, Stillman L, et al. The DOA pathway: studies on the functions and mechanisms of ubiquitin-dependent protein degradation in the yeast Saccharomyces cerevisiae. Cold Spring Harb Symp Quant Biol 1995; 60: 503-13.
101. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991; 67: 547-56.
102. Crook T, Vousden KH. Interaction of HPV E6 with p53 and associated proteins. Biochem Soc Trans 1994; 22: 52-5.
103. Pim D, Storey A, Thomas M, Massimi P, Banks L. Mutational analysis of HPV-18 e6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994; 9: 1869-76.
104. Dalal S, Gao QS, Androphy EJ, Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 1996; 70: 683-8.
105. Nuber U, Schwarz SE, Scheffner M. The ubiquitin-protein ligase E6-associated protein (E6-AP) serves as its own substrate. Eur J Biochem 1998; 254: 643-9.
106. Pim D, Massimi P, Banks L. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 1997; 15: 257-64.
107. Lepik D, Ilves I, Kristjuhan A, Maimets T, Ustav M. p53 protein is a suppressor of papillomavirus DNA amplificational replication. J Virol 1998; 72: 6822-31.
108. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994; 68: 4262-73.
109. Kinoshita T, Shirasawa H, Shino Y, Moriya H, Desbarats L, Eilers M, et al. Transactivation of prothymosin alpha and c-myc promoters by human papillomavirus type 16 E6 protein. Virology 1997; 232: 53-61.
110. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci U S A 1998; 95: 8058-63.
111. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
112. Dyson N, Guida P, Münger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992; 66: 6893-902.
113. Firzlaff JM, Galloway DA, Eisenman RN, Luscher B. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol 1989; 1: 44-53.
114. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993; 7: 872-9.
115. Ciccolini F, Dipasquale G, Carlotti F, Crawford L, Tommasino M. Functional studies of E7 proteins from different HPV types. Oncogene 1994; 9: 2633-8.
116. Massimi P, Pim D, Storey A, Banks L. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996; 12: 2325-30.
117. Massimi P, Banks L. Repression of p53 transcriptional activity by the HPV E7 proteins. Virology 1997; 227: 255-9.
118. Huang PS, Patrick DR, Edwards G. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 1993; 13: 953-60.
119. Davies R, Hicks R, Crook T, Morris J, Vousden K. Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. J Virol 1993; 67: 2521-8.
120. Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R, Contorni M, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993; 8: 195-202.
121. McIntyre MC, Ruesch MN, Laimins LA. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 1996; 215: 73-82.
122. Zerfass K, Levy LM, Cremonesi C, Ciccolini F, Jansen-Durr P, Crawford L, et al. Cell cycle-dependent disruption of E2F-p107 complexes by human papillomavirus type 16 E7. J Gen Virol 1995; 76: 1815-20.
123. Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J 1996; 15: 1950-60.
124. Shan B, Farmer AA, Lee WH. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ 1996; 7: 689-97.
125. Ruesch MN, Laimins LA. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol 1997; 71: 5570-8.
126. Wang YS, Okan I, Pokrovskaja K, Wiman KG. Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. Oncogene 1996; 12: 2731-5.
127. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827-38.
128. Xu C, Meikrantz W, Schlegel R, Sager R. The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc Natl Acad Sci U S A 1995; 92: 7829-33.